BR112013010213A2 - anticorpos que unem ligantes solúveis de receptores de célula t - Google Patents

anticorpos que unem ligantes solúveis de receptores de célula t

Info

Publication number
BR112013010213A2
BR112013010213A2 BR112013010213A BR112013010213A BR112013010213A2 BR 112013010213 A2 BR112013010213 A2 BR 112013010213A2 BR 112013010213 A BR112013010213 A BR 112013010213A BR 112013010213 A BR112013010213 A BR 112013010213A BR 112013010213 A2 BR112013010213 A2 BR 112013010213A2
Authority
BR
Brazil
Prior art keywords
cell receptor
receptor ligands
soluble
antibodies
bind
Prior art date
Application number
BR112013010213A
Other languages
English (en)
Inventor
Reiter Yoram
Dahan Rony
A. Vandenbark Arthur
Original Assignee
Technion Research & Development Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technion Research & Development Foundation Ltd filed Critical Technion Research & Development Foundation Ltd
Publication of BR112013010213A2 publication Critical patent/BR112013010213A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Rehabilitation Therapy (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

anticorpos que unem ligantes solúveis de receptores de célula t. apresenta entidades isoladas de alta definição que compreendem um antígeno ligando o domínio que liga especificamente um ligante solúvel de receptor de célula t compreendendo um beta1-alpha1 de dois domínios de um complexo de histocompatibilidade (mhc) classe ii, caracterizado por o referido antígeno ligando o domínio não ligar um complexo compreendendo alpha1-betal/alpha2-beta2 de quatro domínios de mhc classe ii; também são apresentados métodos e jogos utilizando o mesmo para detecção e segregação de ligantes solúveis de receptor de célula t em uma amostra.
BR112013010213A 2010-10-26 2011-10-26 anticorpos que unem ligantes solúveis de receptores de célula t BR112013010213A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40660910P 2010-10-26 2010-10-26
PCT/IB2011/054775 WO2012056407A1 (en) 2010-10-26 2011-10-26 Antibodies which bind soluble t-cell receptor ligands

Publications (1)

Publication Number Publication Date
BR112013010213A2 true BR112013010213A2 (pt) 2019-09-24

Family

ID=45401105

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013010213A BR112013010213A2 (pt) 2010-10-26 2011-10-26 anticorpos que unem ligantes solúveis de receptores de célula t

Country Status (6)

Country Link
US (1) US20140170168A1 (pt)
EP (1) EP2632955A1 (pt)
BR (1) BR112013010213A2 (pt)
CA (1) CA2816225A1 (pt)
IL (1) IL225965A0 (pt)
WO (1) WO2012056407A1 (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013538555A (ja) 2010-07-15 2013-10-17 テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド Ｍｈｃクラスｉｉとグルタミン酸デカルボキシラーゼ（ｇａｄ）自己抗原性ペプチドとの天然型複合体に対するｔ細胞受容体様特異性を有する単離された高親和性実体
US8685404B2 (en) * 2011-01-31 2014-04-01 Oregon Health & Science University Recombinant T-cell receptor ligand for the treatment of cognitive and neuropsychiatric impairment induced by substance addiction
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
TWI777198B (zh) 2013-08-05 2022-09-11 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（七）
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
WO2015164615A1 (en) * 2014-04-24 2015-10-29 University Of Oslo Anti-gluten antibodies and uses thereof
GB201408255D0 (en) 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
GB201411037D0 (en) 2014-06-20 2014-08-06 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
IL254129B2 (en) 2015-03-27 2023-10-01 Immatics Biotechnologies Gmbh New peptides and a combination of peptides for use in immunotherapy against various tumors
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
GB201507719D0 (en) 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
CN108026154B (zh) 2015-07-01 2022-03-08 伊玛提克斯生物技术有限公司 用于卵巢癌和其他癌症免疫治疗的新型肽和肽组合物
PE20180259A1 (es) 2015-07-06 2018-02-05 Immatics Biotechnologies Gmbh Nuevos peptidos y combinacion de peptidos para usar en inmunoterapia contra el cancer esofagico y otros canceres
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
BR112018002824A2 (pt) * 2015-08-11 2018-11-06 Open Monoclonal Tech Inc anticorpo, polinucleotídeo, vetor, célula, métodos para expressar o anticorpo, para tratar uma condição associada com pd-1 e para tratar uma condição em um sujeito, kit, composição farmacêutica e uso do anticorpo
US10900965B2 (en) 2015-08-24 2021-01-26 University Of Cincinnati Methods and compositions for the detection of Fc receptor binding activity of antibodies
GB201522667D0 (en) 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
WO2017120483A1 (en) * 2016-01-08 2017-07-13 Oregon Health & Science University Recombinant t cell receptor ligand compositions and methods for treatment of prostate cancer
GB201602918D0 (en) 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
MA54832A (fr) 2016-03-01 2021-12-01 Immatics Biotechnologies Gmbh Peptides, combinaison de peptides et médicaments à base de cellules destinés à être utilisés en immunothérapie contre le cancer de la vessie et d'autres cancers
CR20180530A (es) 2016-04-06 2019-03-11 Immatics Biotechnologies Gmbh Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra la leucemia mieloide aguda (lma) y otros tipos de cancer
TWI796299B (zh) 2016-08-26 2023-03-21 德商英麥提克生物技術股份有限公司 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
GB201618432D0 (en) 2016-11-01 2016-12-14 Matn Scient Ltd Detection and treatment of demyelinating diseases
TWI796314B (zh) 2017-01-27 2023-03-21 德商英麥提克生物技術股份有限公司 用於卵巢癌和其他癌症免疫治療的新型肽和肽組合物
SG11201909153UA (en) 2017-04-10 2019-10-30 Immatics Biotechnologies Gmbh Peptides and combination thereof for use in the immunotherapy against cancers
WO2018189148A1 (en) 2017-04-10 2018-10-18 Immatics Biotechnologies Gmbh Peptides and combination thereof for use in the immunotherapy against cancers
US10899819B2 (en) 2017-04-10 2021-01-26 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
WO2019007974A1 (en) 2017-07-07 2019-01-10 Immatics Biotechnologies Gmbh NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF LUNG CANCER, INCLUDING NSCLC, CPPC AND OTHER CANCERS
BR112019028070A2 (pt) 2017-07-07 2020-07-14 Immatics Biotechnologies Gmbh peptídeos e combinações de peptídeos para uso em imunoterapia contra câncer de pulmão, incluindo cpcnp, cppc e outros cânceres
JP2021502122A (ja) * 2017-11-10 2021-01-28 ジュラ バイオ，インコーポレイテッド 主要組織適合複合体ベースのキメラ受容体および自己免疫疾患を治療するためのその使用
DE102018107224A1 (de) 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
TW202016131A (zh) 2018-05-16 2020-05-01 德商英麥提克生物技術股份有限公司 用於抗癌免疫治療的肽
US10925947B2 (en) 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
TW202019955A (zh) 2018-07-31 2020-06-01 德商英麥提克生物技術股份有限公司 B*07 限制肽和肽組合的抗癌免疫治療和相關方法
US11945850B2 (en) 2018-09-17 2024-04-02 Immatics Biotechnologies Gmbh B*44 restricted peptides for use in immunotherapy against cancers and related methods
TW202024121A (zh) 2018-09-18 2020-07-01 德商英麥提克生物技術股份有限公司 A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法
EP4219753A3 (en) * 2018-10-19 2023-09-06 Akoya Biosciences, Inc. Detection of co-occurring receptor-coding nucleic acid segments
TW202039535A (zh) 2018-12-18 2020-11-01 德商英麥提克生物技術股份有限公司 B*08限制肽和肽組合物抗癌免疫治療和相關方法
MX2022000726A (es) * 2019-07-19 2022-02-10 Oncoresponse Inc Anticuerpos inmunomoduladores y metodos de uso de los mismos.
DE102020125457A1 (de) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
TW202229312A (zh) 2020-09-29 2022-08-01 德商英麥提克生物技術股份有限公司 由非ｈｌａ－ａ*０２顯露以用於不同類型癌症之免疫治療的醯胺化肽及其脫醯胺化對應物
DE102020125465A1 (de) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
TW202241925A (zh) 2021-01-15 2022-11-01 德商英麥提克生物技術股份有限公司 用於不同類型癌症免疫治療的ｈｌａ展示肽
US20240084029A1 (en) * 2021-01-20 2024-03-14 Oncoresponse, Inc. Use of immunomodulatory antibodies to treat fibrotic diseases
WO2023187127A1 (en) 2022-03-31 2023-10-05 Enterome S.A. Antigenic peptides for prevention and treatment of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020150914A1 (en) * 1995-06-30 2002-10-17 Kobenhavns Universitet Recombinant antibodies from a phage display library, directed against a peptide-MHC complex
US20040191260A1 (en) * 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US20110008382A1 (en) * 2009-03-07 2011-01-13 Burrows Gregory G Compositions and methods using recombinant MHC molecules for the treatment of uveitis

Also Published As

Publication number Publication date
EP2632955A1 (en) 2013-09-04
US20140170168A1 (en) 2014-06-19
WO2012056407A1 (en) 2012-05-03
IL225965A0 (en) 2013-06-27
WO2012056407A8 (en) 2012-07-12
CA2816225A1 (en) 2012-05-03

Similar Documents

Publication Publication Date Title
BR112013010213A2 (pt) anticorpos que unem ligantes solúveis de receptores de célula t
CY1121536T1 (el) Ανθρωπινα αντισωματα εναντι-αλφα-συνουκλεϊνης
CO2018001405A2 (es) Receptores de antígenos quiméricos basados en anticuerpos de dominio simple
JP2011524537A5 (pt)
PH12018500766A1 (en) Bispecific antibodies with tetravalency for a costimulatory tnf receptor
JO3812B1 (ar) أجسام مضادة ترتبط بالمركب الترابطي البشري للموت المبرمج 1 (pd-l1)
MX2013012143A (es) Inmunoensayo.
WO2012007950A3 (en) Antibodies with t-cell receptor like specificity towards native complexes of mhc class ii and diabetes-associated autoantigenic peptides
MX2017007617A (es) Aparato y metodos de prueba para biomarcador cardiaco st2.
BR112013000985A2 (pt) Entidades isoladas de alta afinidade com especificidade semelhante à do receptor de célula t em relação a complexos nativos de mhc classe ii e peptídeos autoantigênicos de descarboxilase do ácido glutâmico (gad)
EA200702361A1 (ru) АНТИТЕЛА ПРОТИВ csPCNA ИЗОФОРМЫ И ИХ ПРИМЕНЕНИЕ
BR112014025384A8 (pt) método e sistema para executar ensaio automatizado e métodos para executar teste reflexivo em vários exemplares
WO2008120202A3 (en) Antibodies, methods and kits for diagnosing and treating melanoma
WO2010065568A3 (en) METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95
BRPI0812488A2 (pt) Anticorpos anti-cd44 humanizados e quiméricos que mediam citotoxidade de célula de câncer, usos dos mesmos, ensaios de ligação, métodos, composições e kit de ensaio
MX2019001767A (es) Anticuerpos monoclonales que se unen al dominio de union a lipidos de la proteina de la capside del virus de la hepatitis c (vhc).
MX2010000680A (es) Materiales y metodos para selección de esperma sexual.
MX2015003150A (es) Anticuerpos específicos de polipeptido amiloide de islote humano (hiapp) y sus usos.
BR112015022844A2 (pt) métodos para detecção de anticorpos para doadores específicos e sistemas para pratica destes
MX349661B (es) Metodo para la deteccion de una molecula de union de un enlazador multiespecifico.
MX349003B (es) Metodo para la deteccion del asociado de union libre de un aglutinante multiespecifico.
WO2009035738A3 (en) Use of antibody secreting cell elispot to assess antibody responses following antigen exposure
RU2015104737A (ru) Способ обнаружения мультиспецифического связывающего агента
MX2022007404A (es) Materiales y metodos para direccionamiento biologico in vivo.
CL2012003165A1 (es) Metodo para detectar pared de celulas de levadura en una muestra que comprende exponer dicha muestra a un anticuerpo primario capaz de unirse a un antigeno derivado de glucano; composicion que comprende un derivado de glucano ligado a una proteina; anticuerpo monoclonal capaz de unirse al derivado de glucano; metodo para preparar anticuerpos; kit de deteccion .

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.